翻译尚未完成，当前显示原文。
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。
Veytics Intelligence
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
